The host-immune response against adenoviruses forms a major obstacle for their use as gene therapy vectors for treatment of genetic defects. None the less, they are the preferred vectors for in vivo gene transfer in experimental gene therapy protocols for cancer. In this article we demonstrate the antitumor efficacy of adenovirus-mediated transfer of human interleukin-2 cDNA in the rat-CC531 model for hepatic metastases of colorectal cancer: intratumoral administration of 10 8 plaque-forming units of the hIL-2-expressing adenoviral vector, AdCAIL-2, resulted in a cessation of tumor growth in 80% of the injected tumors. In control groups receiving AdCnull, a vector with the same viral backbone, but lacking transgene expression, none of the tumors
Introduction
The ability of interleukin-2 (IL-2) to stimulate antitumor immune responses has led to the application of recombinant IL-2 (rIL-2) in cancer treatment.
1,2 IL-2 exerts its antitumor effects in close proximity to or in the tumor and intratumoral introduction of the IL-2 gene by adenoviral vector-mediated transfer is efficacious in inducing regression of established tumors in various tumor models. [3] [4] [5] [6] Natural killer (NK) cells, cytotoxic T lymphocytes (CTLs) as well as tumor-infiltrating lymphocytes (TILs) stimulated by locally produced IL-2, have been implicated as the main effector cells responsible for tumor regression. 7, 8 Occasionally, the activated antitumor immune response also induces immunological memory against the parental tumor cell line. 4 The intratumoral adenoviral gene therapy approach was initially developed to circumvent the toxic sideeffects observed after high-dose systemic administration of rIL-2. [9] [10] [11] However, in vivo gene therapy approaches with the IL-2 gene have a small therapeutic window: due to IL-2-responded. However, intratumoral treatment with this vector significantly enhanced tumor regression induced by systemic IL-2 protein treatment, which was used as a positive control. In addition we show, by performing delayed-type of hypersensitivity assays, that AdCnull when injected intratumorally enhances recognition of tumor antigens by T lymphocytes to the same extent as intratumoral treatment with the IL-2-expressing vector. The replication-deficient adenoviruses appear to have a therapeutic advantage in cytokinemediated immunotherapy: even adenovirus vectors that do not express a transgene, show adjuvant activity and stimulate an antitumor immune response. Gene Therapy (2000) 7, 1410-1416.
related toxicity the viral dose is often limited. 4, 12 Combining IL-2 with other therapeutic genes such as wild-type p53, HSV-thymidine kinase or IL-12 may lower the required dose, but they also limit their application to tumors sensitive for these additional genes. [13] [14] [15] [16] [17] Whereas systemic treatment with rIL-2 protein has proved its efficacy, 9, 18, 19 the application of recombinant adenoviral vectors (rAd) carrying the IL-2 gene has only been successful after intratumoral administration due to yet unclear causes.
The use of rAd in general is limited by the hostimmune response against the viral vector, prohibiting successive vector administrations. 20, 21 Although this is obviously a major drawback for the treatment of genetic defects, the effect might be additive in stimulating the immune response against tumors.
In this article we describe a feature of rAd vectors that can be exploited in anti-cancer immunotherapies. The aim of this study was to evaluate the intratumoral treatment with a rAd expressing the IL-2 gene (AdCAIL-2) for its ability to induce tumor regression in the CC531 rat model for hepatic colon cancer. Systemic rIL-2 treatment, which has been described to induce tumor regression in this model, was used as a control. In our experiments we have found that rIL-2-induced tumor regression is significantly improved if the treatment is combined with intratumoral injection of a rAd vector that does not express a transgene. In addition, we show by performing delayed-type of hypersensitivity (DTH) assays, that such adenoviral vectors, when injected into the tumor, enhance specific T lymphocyte recognition of antigens derived from the parental tumor cell line.
Apparently the adenoviral vector itself has an adjuvant activity, enhancing tumor regression by stimulating recognition of the tumor cells by specific antitumor T lymphocytes. The immune response to adenoviral vectors which limits their usefulness for some applications, might be beneficial for other strategies that aim at inducing an immune response against the transduced cells.
Results

CC531 cells produce high amounts of bioactive IL-2
The efficacy of adenovirus-mediated gene transfer into cultured CC531 cells has been described previously, 22 and exceeds 95% when a multiplicity of infection (MOI) of 25 or higher is used. To study their capacity to produce bioactive human IL-2 (hIL-2), CC531 cells were infected with the AdCAIL-2 vector. The hIL-2 produced by the infected CC531 cells was biologically active as determined with a CTLL-2 bioassay. High levels of hIL-2 were measured starting at 24 h and reached a maximum at 72 h: one million cells produced up to 1.4 × 10 4 Cetus Units (CU) hIL-2/24 h. AdCnull (mock)-infected CC531 cells did not produce measurable levels of hIL-2.
IL-2 toxicity in the Wag/Rij rat In a previous study, the AdCAIL-2 vector has been shown to be effective in inducing regression of mammary adenocarcinoma in the polyoma middle-T antigen transgenic mouse model. 4 However, the doses required to induce tumor regression were sometimes lethal. To test the toxicity level in the Wag/Rij rat model, increasing amounts of AdCAIL-2, up to doses of 7.5 × 10 8 plaqueforming units (p.f.u.) AdCAIL-2 were injected intraportally and were well tolerated. Higher amounts of the vector, however, caused severe weight loss and rapid deterioration of the animals.
Intratumoral AdCAIL-2 treatment induces regression of subcapsularly implanted CC531 tumors The ability of the AdCAIL-2 vector to induce tumor regression in this model was investigated. The CC531 cell line has been described to be sensitive for IL-2-induced tumor regression when the recombinant IL-2 protein is administered subcutaneously (s.c.) in an optimized interval treatment. 23 This optimized rIL-2 treatment served as a positive control. Tumor-bearing animals (tumors of approximately 30 mm 3 in size) were injected intratumorally with 1 × 10 8 p.f.u. AdCAIL-2 or AdCnull in each tumor (three tumors per liver, thus a total vector exposure of 3 × 10 8 p.f.u.) or with corresponding volumes of virus-dilution buffer (sucrose buffer).
Intratumoral AdCAIL-2 treatment resulted in significant inhibition of tumor growth compared with tumor growth in control animals. Eighty percent of a total of 15 tumors partially regressed, with one instance of complete regression. Tumor growth of AdCAIL-2-treated tumors is depicted in Figure 1a . Statistics are shown in Table 1 . Table 1 .
days, n = 5). Tumor size was measured on day 6 (before injection) and at death (day 21). Tumor growth was determined by calculating the difference of tumor volume between days 6 and 21. Each bar represents the tumor size reduction of one treatment group (n = 5). P values are summarized in
cutaneous treated with rIL-2 were injected either with sucrose buffer or with 1 × 10 8 p.f.u. of AdCnull. Interestingly, the rIL-2-treated animals that received intratumoral AdCnull injections showed a higher percentage (47%) of complete tumor regressions, than those treated with rIL-2 alone (27%). AdCnull injection significantly improved the effect of rIL-2 on tumor regression, resulting in a mean inhibition of tumor growth of 17.5 ± 10.3 mm 3 , compared with a mean inhibition of 9.2 ± 5.6 mm 3 when sucrose buffer was injected into the tumors. The tumor reductions resulting from rIL-2 treatment are depicted in Figure 1b . Statistics have been summarized in Table 1 . The animals did not show overt signs of discomfort with the doses of AdCAIL-2 or rIL-2 used.
Distal untreated tumors show delayed growth after intratumoral treatment with AdCAIL-2 To determine whether in this model a systemic effect is induced by intratumoral treatment with AdCAIL-2, one tumor (left upper liver lobe) was injected intratumorally with the total viral load of 3 × 10 8 p.f.u., 6 days after tumor cell injection. The effect on other untreated tumors implanted in distal liver lobes was examined.
At the moment animals were killed, 21 days after tumor cell injection, the majority of the injected tumors had responded to the treatment with AdCAIL-2 in concordance with the results of the first experiment. The treated left upper tumor almost completely regressed and the growth of the untreated tumors was also inhibited in response to distally given intratumoral treatment. No regression of tumors was seen in animals receiving sucrose buffer or control virus. These data are summarized in Table 2 . AdCAIL-2-treated animals but also AdCnull-treated animals showed positive DTH responses In addition, the animals of the above-mentioned experiment were subjected to DTH assays, to examine whether tumor-specific T lymphocytes were present in AdCAIL-2-treated animals. Freeze/thaw lysates of the implanted CC531 tumor cell line and a Wag/Rij syngeneic control BRK cell line BxC22, were injected into the pinnae of the ears, 6 days after the left upper tumor had been treated. All animals responding to AdCAIL-2 treatment showed positive DTH responses for CC531 challenge, whereas no significant response was seen when the challenge had been with the control cell line BxC22. DTH responses against CC531 lysates of AdCAIL-2-injected animals, but not those of sucrose buffer-injected animals, differed significantly from responses of naive rats, where no CC531 tumors had been implanted. Surprisingly, the animals that received intratumoral AdCnull injections also showed positive DTH responses against CC531 lysates, significantly differing from those observed in sucrose buffer-treated and naive rats and from those against the control BxC22 lysate. In the latter animals, no inhibition of tumor growth was seen in response to AdCnull injections (Figure 2) . Thus, T lymphocytes specifically recognizing CC531 tumor antigens were not only present after AdCAIL-2 treatment, but also after intratumoral injection with the control virus AdCnull. No DTH responses were observed if tumor-bearing sucrose buffer-treated animals or nontumor-bearing naive animals were challenged with Hank's lysate dilution buffer (data not shown).
MHC I molecules expressed on CC531 tumor cells do not show a significant increase after in vitro infection with rAd vectors
Higher immunogenicity of cells may be due to increased presentation of peptides via MHC I or MHC II or, possibly, by stimulated ICAM-1-LFA-1 adhesion through upregulation of ICAM-1. To study whether rAd infection was able to up-regulate MHC I or induce MHC II and ICAM-1 expression on the cell surface, CC531 cells were infected with a MOI of 5 with AdCnull, AdCAIL-2 or wild-type adenovirus type 5 (AdWT5). Subsequently, infected cells were analyzed for MHC I and ICAM-1 expression by flow cytometry, 3, 6, 12, 24 and 48 h after infection. Incubation with recombinant rat IFN␥ was used as a positive control for MHC I up-regulation.
A moderate increase of MHC I expression, normally not seen during the cell cycle of CC531 cells, was observed immediately (3 h) after infection with all rAd vectors used. However, levels had declined to normal already at 6 h after infection and did not change there- 
u., n = 5) or 50 l sucrose buffer (n = 5). In control animals, no tumor was implanted (naive, n = 5). Six days after treatment, the ears of the rats were challenged with freeze/thaw lysates of CC531 cells (black bars) or a syngeneic control cell line BxC22 (hatched bars). Ears were measured at three locations, every 24 h, until 72 h after challenge. Each bar depicts the mean increase in ear size for each treatment group at 48 h after challenge, independently corrected for ear size before challenge. *Challenges with CC531 after AdCAIL-2 and AdCnull treatment show significant difference between groups, compared with the control cell line
Discussion
Despite the presence of tumor-specific T lymphocytes, tumors grow progressively, demonstrating a failure in the development of an effective antitumor immunity. This unresponsiveness can be reverted by challenge with IL-2 in close vicinity of the tumors, breaking tolerance towards peripheral tumor antigens in vivo. 8, 23, 27 Direct intratumoral injection of vectors carrying the IL-2 gene has proven to be a highly effective method for inducing tumor regression.
In this article we report that in rat liver metastases, direct intratumoral injection of adenoviral vectors expressing the IL-2 gene successfully reduced the tumor volume of established tumors. In addition, untreated tumors also showed an inhibition of tumor growth if a distal tumor received a single intratumoral injection of AdCAIL-2. Moreover, we observed that infection with replication-deficient adenoviral vectors that do not express any foreign transgene, when combined with exogenous rIL-2 treatment, served as an adjuvant by reducing tumor volumes. The viral vector stimulated recGene Therapy ognition of tumor antigens by tumor-specific T lymphocytes, as was determined by DTH assays. Although this adenoviral adjuvant activity has been suggested before, 16, 20 its occurrence has not been demonstrated in vivo.
First, we compared an optimized treatment with exogenous rIL-2 protein with intratumoral treatment with the AdCAIL-2 vector in order to study the efficacy of the latter. Intratumoral AdCAIL-2 treatment significantly inhibited the growth of established CC531 tumors. This inhibition increased when a three-fold higher viral dose was administered. Possibly, higher doses of AdCAIL-2 might be even more efficient without causing severe side-effects. The volumes of untreated tumors were also reduced upon treatment of a distal tumor. Although vector leakage cannot be excluded, it does not result in significant transduction of tumor cells in this model (MM van der Eb, SB Geutskens, manuscript in preparation). Alternatively, the observed regression might be induced by the resulting increase in IL-2 concentration within the portal blood circulation.
More importantly, the presence of tumor-specific T lymphocytes was demonstrated by delayed-type of hypersensitivity (DTH) assays, as an indicator for antitumor immunity and vaccine efficacy. 25 The induction of a tumor-specific immune response might well attribute to the observed tumor regression.
Interestingly, when exogenous rIL-2 protein (used as a positive control) is administered alone or in combination with intratumoral injection of an 'empty' rAd vector, tumor growth is significantly inhibited in the latter group. It cannot be excluded that this is due to an antirAd immune response, 20, 21 but the adenoviral vector alone was not able to reduce tumor volumes in any of the experiments performed, probably due to the absence of co-stimulatory signals. By performing DTH assays, we showed that CC531-specific T lymphocytes were present in intratumoral AdCnull-treated animals to the same extent as in AdCAIL-2-treated animals, while they were absent in naive animals and in control animals that received sucrose buffer intratumorally. Anti-adenoviral immunity, therefore, cannot directly explain the observed adjuvant effect and the specific recognition of tumor antigens by T lymphocytes.
Nonspecific up-regulation of MHC class I molecules by rAd infection, due to infection-related stress, might be one explanation for the observed increased immunogenicity of the infected tumor cells. Enhanced MHC I expression can lead to increased presentation of endogenous tumor antigens to cytotoxic T lymphocytes that can subsequently kill the tumor cells. Lipofection-mediated gene transfer has also been shown to induce MHC I upregulation, 26 and in vitro adenovirus-mediated gene transfer to immature human monocyte-derived dendritic cells resulted in enhanced immuno-stimulatory capacity of these cells, through up-regulation of different costimulatory and adhesive molecules. 27 However, infections of cultured CC531 cells with a low dose of rAd vectors led to only moderate increases in MHC I expression immediately after infection. At higher infectious doses, expression levels of MHCI, MHC II and ICAM-1 were unaffected in vitro with all vectors used. Therefore, adenoviral infection is probably not directly responsible for any of the observed effects. The infectious process, however, might lead to an inflammatory reaction and
Figure 3 FACScan analysis of MHC I expression on the surface of CC531 cells after infection with different rAd vectors. CC531 cells were cultured at 60% confluence and infected with AdCnull, AdCAIL-2 or wtAd5 at a MOI of 5. Cells were harvested at 3, 6, 12, 24 and 48 h after infection and analyzed for MHC I expression by flow-cytometry. CC531 cells cultured with recombinant rat IFN␥ (1000 U/ml) served as positive control for MHC I up-regulation and non-infected cells (mock) served as blank. Both control histograms are depicted. Black histograms show background staining with isotype control antibodies and white histograms show MHC I-specific staining. Mean fluorescence intensities are indicated.
subsequent extracellular changes, influencing the expression of co-stimulatory or adhesive molecules of the tumor cells in vivo.
Increased expression of the major heat shock protein 70 (hsp70) has also been described to result in enhanced immunogenicity of tumor cells and higher antigen uptake by dendritic cells after cell lysis. 28 Moreover, the induction of hsp70 expression is a highly specific response seen after wild-type Ad5 infection, especially due to the action of the adenoviral E1A gene. 29 Recently, it has been shown that low contaminating levels of replication-competent adenovirus (RCA) could be responsible for inducing expression of hsp70 to a level effective in enhancing immunogenicity. 30 However, the vector batches used here, which had been produced with the PERC.6 cell line, 31 were found to be RCA negative in PCR for E1A sequences. In accordance with the PCR result, a DTH reaction was absent after challenge with the Ad5-E1A-expressing control cell line, BxC22.
Most likely, the observed adjuvant effect is caused by non-adeno-specific infectious bystander damage, due to cell lysis after infection with high viral doses. Such cell death has been observed for this vector in vitro (MM van der Eb, SB Geutskens, manuscript in preparation). Relatively high levels of cell lysis can result in enhanced uptake of cellular antigens by local antigen-presenting cells, leading to increased presentation and subsequent CD4 + T lymphocyte activation by tumor-specific antigen. This is similar to what has been described for Coxsackie virus infections. 32, 33 Thus, the observed adjuvant activity after intratumoral injection with rAd vectors may lower the threshold for induction of an antitumor immune response. This can explain why intratumoral injection of viral vectors carrying cytokine genes is often successful, while in the same model, systemic delivery of such genes is not.
Materials and methods
Cells and cell culture The CC531 cell line is a 1,2-dimethylhydrazine-induced, moderately differentiated adenocarcinoma of the colon, syngeneic with Wag/Rij rats. 34 The BxC22 cell line was generated by transplantation of kidney cells from neonatal Wag/Rij rats with a plasmid, pAd5 XhoI, carrying the adenovirus type 5 E1 region. 35 The cell lines were maintained in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 50 g/ml streptomycin and 50 g/ml penicillin or minimum essential medium Eagle's medium (MEM) supplemented with 10% newborn calf serum, 50 g/ml streptomycin and 50 g/ml penicillin, respectively, at 37°C/5% CO 2 .
Viruses and viral techniques Construction of the recombinant adenoviral vector AdCAIL-2 expressing the human IL-2 gene under the control of the cytomegalovirus enhancer/promoter (CMV) has been reported previously. 4 For control experiments AdCMV␤Gal 36 and AdCnull (identical backbone but no foreign transgene inserted) were used. Virus was propagated on PERC.6 cells, 31 harvesting and purification have been described earlier. 35 Stocks were free from replication-competent adenoviruses (RCA) as tested with PCR (PCR sensitivity approximately 1 RCA per 5 × 10 7 p.f.u.), as described. 37 In vitro IL-2 expression CC531 cells were infected with AdCAIL-2 at a MOI of 10 p.f.u. per cell in DMEM supplemented with 2% horse serum (GIBCO BRL, Life Technologies, Auckland, New Zealand). Every 24 h, supernatant was snap-frozen and stored at −70°C. Bioactivity was determined and levels of secreted hIL-2 were quantified by CTLL-2 proliferation in a bioassay. 38 The various supernatant dilutions were incubated for 20 h with 0.6 Ci per well 3 H-thymidine. CTTL-2s were harvested after 6 h and tritium incorporation was measured.
Tumor model Male
Wag/Rij rats (Harlan/CPB, Zeist, The Netherlands), weighing 200-250 g, were used for in vivo experiments. Animals were fed ad libitum and housed in filter-top cages in DII level biosafety facilities. All experiments were approved by the Institute's animal experiments committee.
Harvesting of CC531 cells and subcapsular liver injection of tumors by performing laparotomy have been described previously. 22 In every rat, three tumors were injected, each on a different liver lobe. On day 21 after tumor cell injection, animals were killed and tumors were measured with microcalipers. Tumor sizes were calculated with the formula: (maximum tumor length) 2 × tumor width/2.
For in vivo gene transfer, rats were re-opened 6 days after tumor cell injection and tumors were measured; subsequently 40 l of adenovirus containing suspension or solvent suspension (5% sucrose in TD buffer) was injected into the tumor with 500 l insulin syringes (Becton Dickinson, Dublin, Ireland).
Recombinant IL-2 treatment
The interval treatment with high doses of rIL-2 (Chiron, Amsterdam, The Netherlands) has already been reported to induce tumor regression in this model. 23 Briefly, rats subcutaneously received 2 × 10 5 CU in 0.5 ml 0.9% (w/v) NaCl solution buffered with 1.4 mm phosphate, in the scruff of the neck, at 8 h intervals for 3 days. The treatment started 6 days after tumor cell injection.
DTH assays CC531 cells and BxC22 cells were harvested by trypsinization, washed three times with PBS and diluted in Hank's balanced salt solution, to a concentration of 1 × 10 6 cells/20 l. Cells were cracked by repeating (10 ×) of quick freeze/thaw steps. The absence of cell viability was determined by culturing cracked suspensions for 48 h.
Before challenge, ears were measured three times with microcalipers. The pinnae of the right ear was injected with 20 l of CC531 suspension, the pinnae of the left ear with 20 l of BxC22 suspension. Ear swelling was measured at three different locations every 24 h, until 72 h after challenge. Observers were blinded to the treatment and the challenge antigen used. Naive rats, without CC531 tumors implanted, served as controls.
Gene Therapy
FACScan analysis
The expression levels of MHC I, MHC II and ICAM-1 on the cell surface of CC531 cells were determined before and after infection with the various rAds, by flow cytometry analysis. A million cells (at 60% confluency) were infected with AdCAIL-2, AdCnull and AdWT5 at a MOI of 5 in a first and a MOI of 25 and 125 in a second experiment. Cells were harvested 3, 6, 12, 24 and 48 h after infection, washed with PBS and fixed in 4% paraformaldehyde. Non-infected cells and cells incubated for 48 h with recombinant rat-IFN␥ (1000 U/ml) 39 served as controls. Cells were stained at 4°C for 30 min in PBS supplemented with 0.5% BSA, followed by staining with FITC-conjugated goat anti-mouse IgG/M antibody (Dako, Glostrup, Denmark) and analyzed by flow cytometry (FACScalibur, Becton Dickinson, Mountain View, CA, USA). The following antibodies were used: Ox18 (mouse anti-rat MHC cI I (RT1.A/C)), Ox6 (mouse antirat MHC cI II (RT1.B)) and 1A29 (mouse anti-rat ICAM-1). 40, 41 To verify proper infection of cells, AdCMV␤Gal-infected cells were permeabilized by incubation with PBS/0.5% BSA/0.2% saponin for 15 min at RT and washed twice with PBS/0.5% BSA/0.2% saponin. Permeabilized cells were stained on ice with Rabbit anti-␤Gal IgG (Cappel 55978; ICN Biomedicals, Zoetermeer, The Netherlands) for 30 min, washed twice with PBS/0.5% BSA/0.2% saponin, followed by staining with FITC-conjugated Swine anti-rabbit IgG/M antibody (Dako) and analyzed by flow cytometry.
Statistics P values were calculated with the Student's t test.
